Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment

被引：24

作者：

Benjamin, Robert S. ^{[9
]}

Debiec-Rychter, Maria ^{[8
]}

Le Cesne, Axel ^{[7
]}

Sleijfer, Stefan ^{[6
]}

Demetri, George D. ^{[5
]}

Joensuu, Heikki ^{[4
]}

Schoeffski, Patrick ^{[2
,3
]}

Poveda, Andres ^{[1
]}

机构：

[1] Inst Valenciano Oncol, Valencia 46009, Spain

[2] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[3] Katholieke Univ Leuven, Leuven Canc Inst, Expt Oncol Lab, Leuven, Belgium

[4] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland

[5] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA

[6] Erasmus Univ, Med Ctr, Dept Med Oncol, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands

[7] Inst Gustave Roussy, Villejuif, France

[8] Katholieke Univ Leuven, Dept Human Genet, Leuven, Belgium

[9] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA

来源：

SEMINARS IN ONCOLOGY | 2009年 / 36卷 / 04期

关键词：

EORTC-SOFT-TISSUE; POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; IMATINIB MESYLATE; PHASE-I; DOSE IMATINIB; ADVANCED MALIGNANCIES; ACQUIRED-RESISTANCE; VARYING DEGREES;

D O I：

10.1053/j.seminoncol.2009.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The finding of mutations of KIT in gastrointestinal stromal tumors (GISTs) and subsequent development of kinase-directed therapy in metastatic GIST serve as a touchstone for the translation of laboratory research into clinical therapeutics. A variety of novel developments have followed the discovery of clinical activity of kinase-directed therapy against GIST. Radiological assessment of GIST challenges the standard of care for assessing tumor responses, ie, Response Evaluation Criteria in Solid Tumors (RECIST). Furthermore, the determination of the relationship of specific KIT mutations and sensitivity and resistance to kinase-directed agents and the assessment of inhibitor levels and the quality of response to those agents have implications beyond the treatment of sarcomas. These discoveries and the next chapters in this developing story are discussed in this review. © 2009.

引用

页码：302 / 311

页数：10

共 63 条

[1] Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].

Antonescu, CR ;

Besmer, P ;

Guo, TH ;

Arkun, K ;

Hom, G ;

Koryotowski, B ;

Leversha, MA ;

Jeffrey, PD ;

Desantis, D ;

Singer, S ;

Brennan, MF ;

Maki, RG ;

DeMatteo, RP .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190

[2] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[3] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].

Blanke, Charles D. ;

Demetri, George D. ;

von Mehren, Margaret ;

Heinrich, Michael C. ;

Eisenberg, Burton ;

Fletcher, Jonathan A. ;

Corless, Christopher L. ;

Fletcher, Christopher D. M. ;

Roberts, Peter J. ;

Heinz, Daniela ;

Wehre, Elisabeth ;

Nikolova, Zariana ;

Joensuu, Heikki .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625

[4] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].

Blanke, Charles D. ;

Rankin, Cathryn ;

Demetri, George D. ;

Ryan, Christopher W. ;

von Mehren, Margaret ;

Benjamin, Robert S. ;

Raymond, A. Kevin ;

Bramwell, Vivien H. C. ;

Baker, Laurence H. ;

Maki, Robert G. ;

Tanaka, Michael ;

Hecht, J. Randolph ;

Heinrich, Michael C. ;

Fletcher, Christopher D. M. ;

Crowley, John J. ;

Borden, Ernest C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632

[5]

Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183

[6]

Bui BN, 2007, J CLIN ONCOL, V25

[7] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps [J].

Burger, H ;

van Tol, H ;

Brok, M ;

Wiemer, EAC ;

de Bruijn, EA ;

Guetens, G ;

de Boeck, G ;

Sparreboom, A ;

Verweij, J ;

Nooter, K .

CANCER BIOLOGY & THERAPY, 2005, 4 (07) :747-752

[8] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[9] PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib [J].

Corless, CL ;

Schroeder, A ;

Griffith, D ;

Town, A ;

McGreevey, L ;

Harrell, P ;

Shiraga, S ;

Bainbridge, T ;

Morich, J ;

Heinrich, MC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5357-5364

[10] Clinical pharmacology: Concise drug reviews [J].

De Kogel, Christine E. ;

Schellens, Jan H. M. .

ONCOLOGIST, 2007, 12 (12) :1390-1394

← 1 2 3 4 5 6 7 →